Research advances in NQO1-responsive prodrugs and nanocarriers for cancer treatment

Yang Xiaojuan; Duan Jiaxue; Wu Liqiang

首页> 外文期刊>Future medicinal chemistry >Research advances in NQO1-responsive prodrugs and nanocarriers for cancer treatment

【24h】

Research advances in NQO1-responsive prodrugs and nanocarriers for cancer treatment

机译：Research advances in NQO1-responsive prodrugs and nanocarriers for cancer treatment

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

NAD(P)H: quinine oxidoreductase (NQO1) is a class of flavoprotein enzymes commonly expressed in eukaryotic cells. It actively participates in the metabolism of various quinones and their in vivo bioactivation through electron reduction reactions. The expression level of NQO1 is highly upregulated in many solid tumor cells compared with that in normal cells. NQO1 has been considered a candidate molecular target because of its overexpression and bioactivity in different tumors. NQO1-responsive prodrugs and nanocarriers have recently been identified as effective objectives for achieving controlled drug release, reducing adverse reactions and improving clinical efficacy. This review systematically introduces the research advances in applying NQO1-responsive prodrugs and nanocarriers to cancer treatment. It also discusses the existing problems and the developmental prospects of these two antitumor drug delivery systems.

著录项

来源
《Future medicinal chemistry》 |2022年第5期|363-383|共21页
作者
Yang Xiaojuan; Duan Jiaxue; Wu Liqiang;
展开▼
作者单位

Sch Pharm,Xinxiang Univ;

Sch Pharm,Xinxiang Med Univ;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类药学;
关键词
antitumor; NQO1; NQO1-responsive nanocarriers; NQO1-responsive prodrugs; stimuli-responsive nanocarriers; STIMULI-RESPONSIVE NANOCARRIERS; OXIDOREDUCTASE 1 NQO1; DRUG-DELIVERY; DT-DIAPHORASE; PHOTODYNAMIC THERAPY; POLYMERIC MICELLES; BIOLOGICAL EVALUATION; RELEASE; ACTIVATION; HYPOXIA;

Research advances in NQO1-responsive prodrugs and nanocarriers for cancer treatment

摘要

著录项

相关主题

期刊订阅